Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Women have lower one-year mortality rates after TAVR with the Sapien valve

Women undergoing transcatheter aortic valve replacement (TAVR) had a lower mortality rate one year after the procedure compared with men, according to a secondary analysis of the PARTNER (Placement of Aortic Transcatheter Valves) trial.

Mended Hearts launches LVAD video contest

Mended Hearts, a heart patient support network, launched a video contest on Feb. 18 for people who have received a left ventricular assist device (LVAD) to treat heart failure.

Thumbnail

ACC announces late-breaking clinical trials for annual scientific session

The American College of Cardiology (ACC) announced the late-breaking clinical trials sessions for its 65th annual scientific session. The conference is taking place from April 2 to 4 at the McCormick Place convention center in Chicago.

Thumbnail

Edwards Lifesciences’ TAVR sales increase 25 percent in fourth quarter

Led by strong sales in its transcatheter heart valve therapy (THV) division, Edwards Lifesciences’ fourth quarter revenue in 2015 increased 8.6 percent and its GAAP earnings per share increased 28.0 percent compared with the same period a year earlier.

Thumbnail

Trial results show mortality rates following TAVR decreased over time

Patients enrolled in a major clinical trial who underwent transfemoral transcatheter aortic valve replacement (TF-TAVR) in late 2011/early 2012 had significant declines in 1- and 2-year all-cause mortality compared with those who had the procedure performed earlier.

Seven researchers receive nearly $800,000 to examine congenital heart defect

The American Heart Association (AHA) and the Children’s Heart Foundation (CHF) announced on Jan. 27 that they had awarded nearly $800,000 in grants to seven research projects in six states.

Bradycardia may not be associated with an increased risk of cardiovascular disease or mortality

After adjusting for risk factors and potential confounders, researchers found that bradycardia was not associated with an increased risk for cardiovascular disease or mortality, according to a retrospective analysis.

Thumbnail

Same-day discharge for TAVR marks new procedural milestone

One morning last year, a patient checked into a hospital in Canada as the first TAVR case of the day, and they were discharge by that evening. It was an eyebrow-raising feat for a procedure that typically requires several days of hospitalization.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.